Single-Digit Restenosis Rates Justify Coated Stent Price Premium - Guidant
This article was originally published in The Gray Sheet
Executive Summary
Guidant expects its paclitaxel-coated stent agreement with Cook, Inc. to yield at least a $1,000 price premium over conventional coronary stents in the U.S.
You may also be interested in...
Drug-Coated Stents Will Pay Their Way If Priced At $2,500 Or Below – Cohen
The ability of drug-eluting stents to reduce the need for revascularization procedures justifies a price premium of up to $1,500 over regular stents, according to a cost-efficiency model by cardiologist David Cohen, MD, Beth Israel Deaconess Medical Center
Drug-Coated Stents Will Pay Their Way If Priced At $2,500 Or Below – Cohen
The ability of drug-eluting stents to reduce the need for revascularization procedures justifies a price premium of up to $1,500 over regular stents, according to a cost-efficiency model by cardiologist David Cohen, MD, Beth Israel Deaconess Medical Center
Boston Scientific Disputes Cook Collaboration With Guidant On Coated Stents
Favorable six-month results from a Cook 21-patient, paclitaxel-coated coronary stent pilot study, including zero restenosis, appear to bode well for the larger ELUTES European study. Six-month ELUTES data are slated to be released at the American Heart Association meeting in November.